Emergent BioSolutions Inc., a global life-sciences company with contract biomanufacturing services, opened its newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore, Maryland. The facility is one of three centers designated by the US Department of Health and Human Services to provide advanced development and manufacturing of medical countermeasures to support the US. government’s national security and public health emergency needs.

Emergent has doubled the Bayview facility’s footprint to 112,000 square feet with investments to the original 56,000-square-foot facility purchased by the company in 2009. The facility, comprised of laboratory, manufacturing, and office space, offers manufacturing of drug substance from microbial, cell culture or viral production platforms and is equipped with disposable manufacturing technology. The new suite within the expanded facility is expected to come on line with cGMP production capabilities in late 2018.

Since its inception, the Emergent CIADM has been awarded four task orders by the Biomedical Advanced Research and Development Authority, part of the US Health and Human Services Department, to develop Ebola and Marburg therapeutics and a Zika vaccine. Emergent also successfully manufactured some of its product candidates at the CIADM and an Ebola vaccine candidate as part of a third-party collaboration.

Emergent employs approximately 1,200 employees worldwide. More than 500 employees are located across four sites in Maryland, including its Bayview campus, Camden manufacturing facility, and corporate headquarters and product development site in Gaithersburg.

Source: Emergent BioSolutions